Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance

AIDS

Volumn 20, Issue 7, 2006, Pages 1071-1073

  De Mendoza, Carmen ^a   Valer, Luisa ^a   Bacheler, Lee ^b   Pattery, Theresa ^c   Corral, Angélica ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b VircoLab Inc   (United States)

^c Virco BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALFETAMINE; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; INDINAVIR; ISOLEUCINE; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS MUTATION;

CARBAMATES; CODON; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MUTATION; NELFINAVIR; PHENOTYPE; PYRIMIDINONES; RITONAVIR; SAQUINAVIR; SULFONAMIDES;

EID: 33646381660     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222084.44411.cc     Document Type: Article

References (20)

1. Hicks C, King M, Gulick R, Clinton-White A, Eron J, Kessker H, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18:775-779.
2. Kempf D, King M, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189:51-60.
3. Eron J, Feinberg J, Kessler H, Horowitz H, Witt M, Carpio F, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48 week randomized clinical trial. J Infect Dis 2004; 189:265-272.
4. Friend J, Parkin N, Liegler T, Martin J, Deeks S. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18:1965-1966.
5. Conradie F, Sanne I, Venter W, Eron J. Failure to lopinavir-ritonavir (Kaletra) containing regimen in an antiretroviral-naive patient. AIDS 2004; 18:1084-1085.
6. Kagan R, Shenderovich M, Ramnarayan K, Heseltine P. Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization. Antivir Ther 2003; 8:S54.
7. Shafer R, Kantor R, Gonzales M. The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev 2000; 2:211-228.
8. Carrillo A, Stewart K, Sham H, Norbeck D, Kohlbrenner W, Leonard J, et al. In vitro selection and characterization of HIV type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72:7532-7541.
9. Hertogs K, de Bethune M, Miller V, Ivens M, Schel P, Van Cauwenberge A, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV-1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269-276.
10. Hugen P, Verweij van Wiseen C, Burger D. Simultaneous determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed phase high-performance liquid chromatography. J Chromatogr B 1999; 727:139-149.
11. Johnson V, Brun-Vezinet F, Clotet B, Conway B, D'Aquila R, Demeter L, et al. Update of the drug resistance mutations in HIV-1: 2004. Topics HIV Med 2004; 12:119-124.
12. Breilh D, Pellegrin I, Rouzes A, Berthoin K, Xuereb F, Budzinski H, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (Kalephar study). AIDS 2004; 18:1305-1310.
13. Kempf D, Isaacson J, King M, Brun S, Sylte J, Richards B, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1 infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002; 7:165-174.
14. Voigt E, Wasmuth C, Vogel M, Mauss S, Schumtz C, Kaiser R, Rockstroh J. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48 week results. Infection 2004; 32:82-88.
15. De Mendoza C, Martín-Carbonero L, Barreiro P, Diaz B, Valencia E, Jimenez-Nacher I, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002; 3:304-309.
16. Sham H, Kempf D, Molla A, Marsh K, Kumar G, Chen C, et al. ABT-378: a highly potent inhibitor of the HIV protease. Antimicrob Agents Chemother 1998; 42:3218-3224.
17. Bongiovanni M, Bini T, Adorni F, Meraviglia P, Cappetti A, Tordato F, et al. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir related mutations. Antivir Ther 2003; 8:209-214.
18. Gonzalez de Requena D, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20:275-278.
19. Parkin N, Chappey C, Petropoulos C. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17:955-961.
20. Rodés B, Toro C, Sheldon J, Jiménez V, Mansinho K, Soriano V. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 2006; 20:127-129.